Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer-Daniels-Midland Co (ADM) vs BioNTech SE - ADR (BNTX) Price & Performance

Archer-Daniels-Midland CoTrade
BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

Archer-Daniels-Midland Co vs BioNTech SE - ADR — how do they compare? Archer-Daniels-Midland Co trades at $79.87 (market cap $38.78B), while BioNTech SE - ADR trades at $93 (market cap $23.31B). The key difference: Archer-Daniels-Midland Co is the larger of the two by market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

ADMBNTX
Market Cap
$38.78B$23.31B
Sector
Consumer StaplesHealth
52-Week High
$87.32$119.34
52-Week Low
$56.00$83.89
Enterprise Value
$47.03B$6.60B
Dividend Yield
2.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer-Daniels-Midland Co

ADM trades at $80.49, up 5.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has declined from $101.6B in 2022 to $80.3B in 2025, but net income margin improved to 2.16% in 2025. The company raised its 2026 outlook after Q2 results, citing biofuels and nutrition strength. Valuation ratios include a P/E of 21.98 and P/S of 0.48, indicating potential undervaluation relative to earnings growth prospects.

Outlook is positive with analyst consensus price target of $88.00, though execution risks and competitive pressures remain. Investment opportunity lies in continued margin expansion and biofuel demand, while risks include volatile commodity prices and debt levels. The stock offers a dividend yield supported by 379 consecutive quarterly payments.

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.

The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.

Returns comparison

Trailing returns across standard periods

About Archer-Daniels-Midland Co

Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.

Read more on ADM

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX